RT Journal Article
SR Electronic
T1 Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.13.21256639
DO 10.1101/2021.05.13.21256639
A1 Heath, Paul T.
A1 Galiza, Eva P.
A1 Baxter, David Neil
A1 Boffito, Marta
A1 Browne, Duncan
A1 Burns, Fiona
A1 Chadwick, David R.
A1 Clark, Rebecca
A1 Cosgrove, Catherine
A1 Galloway, James
A1 Goodman, Anna L.
A1 Heer, Amardeep
A1 Higham, Andrew
A1 Iyengar, Shalini
A1 Jamal, Arham
A1 Jeanes, Christopher
A1 Kalra, Philip A.
A1 Kyriakidou, Christina
A1 McAuley, Daniel F.
A1 Meyrick, Agnieszka
A1 Minassian, Angela M.
A1 Minton, Jane
A1 Moore, Patrick
A1 Munsoor, Imrozia
A1 Nicholls, Helen
A1 Osanlou, Orod
A1 Packham, Jonathan
A1 Pretswell, Carol H.
A1 Francisco Ramos, Alberto San
A1 Saralaya, Dinesh
A1 Sheridan, Ray P.
A1 Smith, Richard
A1 Soiza, Roy L.
A1 Swift, Pauline A.
A1 Thomson, Emma C.
A1 Turner, Jeremy
A1 Viljoen, Marianne Elizabeth
A1 Albert, Gary
A1 Cho, Iksung
A1 Dubovsky, Filip
A1 Glenn, Greg
A1 Rivers, Joy
A1 Robertson, Andreana
A1 Smith, Kathy
A1 Toback, Seth
YR 2021
UL http://medrxiv.org/content/early/2021/05/14/2021.05.13.21256639.abstract
AB Background Covid-19 vaccines are urgently needed, especially against emerging variants. NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 rS) nanoparticle vaccine containing trimeric full-length SARS-CoV-2 spike glycoprotein and Matrix-M adjuvant.Methods A phase 3, randomized, observer-blinded, placebo-controlled trial was conducted in adults 18-84 years old who received two intramuscular 5-µg doses, 21 days apart, of NVX-CoV2373 or placebo (1:1) across 33 sites in the United Kingdom. The primary efficacy endpoint was virologically confirmed symptomatic Covid-19 with onset 7 days after second vaccination in serologically negative participants.Results A total of 15,187 participants were randomized, of whom 7569 received NVX-CoV2373 and 7570 received placebo; 27.2% were 65 years or older, 44.7% had comorbidities and 4.2% had baseline serological evidence of SARS-CoV-2. There were 10 cases of Covid-19 among NVX-CoV2373 recipients and 96 cases among placebo recipients, with symptom onset at least 7 days after second vaccination; NVX-CoV2373 was 89.7% (95% confidence interval, 80.2 to 94.6) effective in preventing Covid-19, with no hospitalizations or deaths reported. There were five cases of severe Covid-19, all in the placebo group. Post hoc analysis revealed efficacies of 96.4% (73.8 to 99.5) and 86.3% (71.3 to 93.5) against the prototype strain and B.1.1.7 variant, respectively. Vaccine efficacy was similar across subgroups, including participants with comorbidities and those ≥65 years old. Reactogenicity was generally mild and transient. The incidence of serious adverse events was low and similar in the two groups.Conclusion A two-dose regimen of NVX-CoV2373 conferred 89.7% protection against a blend of prototype and variant Covid-19, demonstrated high efficacy against the B.1.1.7 variant, and had a reassuring safety profile.(Funded by Novavax, Inc. EudraCT number, 2020-004123-16).Competing Interest StatementDisclosure forms provided by the authors will be available with the full text of this article upon publication.Clinical TrialNCT04583995Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04583995 https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004123-16/GB Funding StatementFunded by Novavax, Inc. EudraCT number, 2020-004123-16Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial protocol was approved by the North West-Greater Manchester Central Research Ethics Committee (Ref 20/NW/03/99) and was performed in accordance with the International Council for Harmonisation Good Clinical Practice guidelines (see protocol in the Supplementary Appendix).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesLimited data will be available on the following websites: https://clinicaltrials.gov/ct2/show/NCT04583995 https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004123-16/GB